Indication intelligence, analysis and sector perception

RegMed’s mid-day: it’s ugly, focus on a rebound as fear will abate!

September 22, 2015 1:05pm

The question is who will be the ghostbusters? My expectation is still that the sector will fall further to the downside and then pivot to the upside!

Have you missed me and today’s mid-day’s updates? Subscribe: http://www.regmedinvestors.com/user/register

Stocks mentioned in the mid-day report: StemCells (STEM), bluebird bio (BLUE), Intrexon (XON), Cellectis ADR (CLLS), Organovo (ONVO), Regenxbio (RGNX), Asterias (NYSEMKT: AST), Neuralstem (CUR), Cesca Therapeutics (KOOL), Spark Therapeutics (ONCE), VistaGen (VSTA) and Athersys (ATHX)

The market that's gripped with fear, fear of uncertainty! Biotech and ethical drug stocks continued to get hammered a second straight session as the major averages slumped en masse Tuesday. By lunch time, the S&P 500 dove 1.6% and traded just above session lows. The Dow was off 1.6%, making mincemeat of Monday's rebound. The NASDAQ gapped lower at the open and was down 2%. Volume was running at much swifter pace on the NYSE but at a mildly higher rate on the NASDAQ. On both exchanges, losing stocks swamped winners by a nearly 5-1 ratio.

The NASDAQ is DOWN -101.49 or -2.10% to 4,727.48 and the DOW is also DOWN -276.88 or -1.68% to 16,233.31.

Pre-open:

Lower open expected; RegMed put an ear on the rail to figure out what’s going on! - See more at: http://www.regmedinvestors.com/articles/lower-open-expected-regmed-put-ear-rail-figure-out-what-s-going#sthash.4XZiYJ5O.dpuf

Research notes:

Caladrius Biosciences (CLBS) and Sanford Research establish collaboration in treatment of Type 1 Diabetes - HOLD - See more at: http://www.regmedinvestors.com/articles/caladrius-biosciences-clbs-and-sanford-research-establish-collaboration-treatment-type-1#sthash.yuMDZVOF.dpuf

Ocata Therapeutics (OCAT) HMCTM cell therapy in a large animal model achieves evidence of remission in Crohn’s Disease - HOLD - See more at: http://www.regmedinvestors.com/articles/ocata-therapeutics-ocat-hmctm-cell-therapy-large-animal-model-achieves-evidence-remission#sthash.Iubmpvq4.dpuf

BOD and C-suite:

ImmunoCellular Therapeutics (NYSEMKT: IMUC) Adds two new BOD members - See more at: http://www.regmedinvestors.com/articles/immunocellular-therapeutics-nysemkt-imuc-adds-two-new-bod-members#sthash.BiSaSH7j.dpuf

A day in the life of the stem, cell and gene therapy RegMed SCGT & RM sector and market:

It ain’t just ugly but, f’ugly!

But, which … ghostbusters will defeat the demon “downside”, we need to reverse the polarity of the stem, cell, gene therapy regenerative medicine (SCGT&RM) sector by crossing the energy streams of the trading programs with protein bars rich in testosterone (which I had warned them to do) and fire a few CEOs and IR firms.

Any distortion in stress can be solved by … demand!

If sector participants can … wipe themselves of the BS or lazy goo, many of “our” universe’s Ghostbusters will be welcomed on the “street” as heroes.

The stem, cell, gene therapy and regenerative medicine (SCGT & RM) equities opened with a negative A/DL of 8/33 and 2 flats followed by a negative mid-day A/DL of 5/37 and 1 flat;

The CBOE Volatility Index (.VIX), widely considered the best gauge of fear in the market, ticked higher to trade near 23 as compared to yesterday’s 22.

Dosing the sector – 43 Patients:

Open: NEGATIVE with 33 decliners, 8 advancers and 2 flats;

1^st hour (10:30 am): NEGATIVE 35 decliners, 7 advancers and 1 flat;

2^nd hour (11:30 am): NEGATIVE with 38 decliners, 4 advancers and 1 flat;

Mid-day (12:30 pm) NEGATIVE with 37 decliners, 5 advancers and 1 flat;

The morning’s indexes in review:

The iShares Nasdaq Biotechnology ETF (IBB) is DOWN -11.24 or -3.30% after Monday’s close -16.29 or – 4.57%;

The Russell 2000 (IWM) is DOWN -2.11 or -1.83% after Monday’s close of -0.21 or -0.18%;

The SPDR SD&P Biotech ETF (XBI) is DOWN -2.81 or -3.73% after Monday’s close of-4.28 or -5.39%;

The CBOE Volatility Index (.VIX) trades at 22 after Monday's close of below 22

Who is down – lowest 5?

bluebird bio (BLUE) is down -$8.19 to $119.25;

Regenxbio (RGNX) -$2.06 to $27.75;

Spark Therapeutics (ONCE) -$1.79 to $43.20;

Cellectis ADR (CLLS) - $1.52 to $31.08;

Intrexon (XON) is down -$1.57 to $45.81;

Who is UP – the only “5”?

Organovo (ONVO) is up +$0.10 to $3.73;

Asterias (NYSEMKT: AST) +$0.15 to $5.92;

Neuralstem (CUR) +$0.02 to $1.53;

Athersys (ATHX) +$0.01 to $1.35;

Cesca Therapeutics (KOOL) +$0.0011 to $0.65

Who is flat?

VistaGen (VSTA) at $9.25

I bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of I-Banking.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities as referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.